(NASDAQ: AKBA) Akebia Therapeutics's forecast annual revenue growth rate of 2.97% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Akebia Therapeutics's revenue in 2026 is $236,196,000.On average, 7 Wall Street analysts forecast AKBA's revenue for 2026 to be $60,797,872,083, with the lowest AKBA revenue forecast at $39,718,454,767, and the highest AKBA revenue forecast at $75,185,666,010. On average, 7 Wall Street analysts forecast AKBA's revenue for 2027 to be $47,320,867,569, with the lowest AKBA revenue forecast at $31,240,076,852, and the highest AKBA revenue forecast at $53,385,653,540.
In 2028, AKBA is forecast to generate $69,069,982,984 in revenue, with the lowest revenue forecast at $49,686,241,250 and the highest revenue forecast at $104,438,078,909.